- Home
- GAMB vs FHTX Comparison
GAMB vs FHTX Comparison
Compare GAMB & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAMB
- FHTX
- Stock Information
- Founded
- GAMB 2006
- FHTX 2015
- Country
- GAMB Jersey
- FHTX United States
- Employees
- GAMB N/A
- FHTX N/A
- Industry
- GAMB Services-Misc. Amusement & Recreation
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- GAMB Consumer Discretionary
- FHTX Health Care
- Exchange
- GAMB Nasdaq
- FHTX Nasdaq
- Market Cap
- GAMB 273.9M
- FHTX 278.1M
- IPO Year
- GAMB 2021
- FHTX 2020
- Fundamental
- Price
- GAMB $7.68
- FHTX $4.12
- Analyst Decision
- GAMB Strong Buy
- FHTX Strong Buy
- Analyst Count
- GAMB 8
- FHTX 5
- Target Price
- GAMB $15.13
- FHTX $11.80
- AVG Volume (30 Days)
- GAMB 707.3K
- FHTX 259.3K
- Earning Date
- GAMB 11-13-2025
- FHTX 10-31-2025
- Dividend Yield
- GAMB N/A
- FHTX N/A
- EPS Growth
- GAMB N/A
- FHTX N/A
- EPS
- GAMB 0.40
- FHTX N/A
- Revenue
- GAMB $147,655,000.00
- FHTX $24,173,000.00
- Revenue This Year
- GAMB $38.41
- FHTX $42.43
- Revenue Next Year
- GAMB $11.58
- FHTX $14.77
- P/E Ratio
- GAMB $19.38
- FHTX N/A
- Revenue Growth
- GAMB 27.57
- FHTX N/A
- 52 Week Low
- GAMB $7.36
- FHTX $2.95
- 52 Week High
- GAMB $17.14
- FHTX $9.70
- Technical
- Relative Strength Index (RSI)
- GAMB 42.19
- FHTX 40.74
- Support Level
- GAMB $7.55
- FHTX $3.85
- Resistance Level
- GAMB $7.90
- FHTX $4.14
- Average True Range (ATR)
- GAMB 0.29
- FHTX 0.29
- MACD
- GAMB 0.03
- FHTX 0.00
- Stochastic Oscillator
- GAMB 43.24
- FHTX 48.45
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.